Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FSME-IMMUN
- Development stage
- Approved
- Lead developer
- Takeda
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
FSME-IMMUN is an inactivated whole-virus vaccine indicated for active immunization against tick-borne encephalitis (TBE), a viral infection of the brain and spine caused by the tick-borne encephalitis virus (TBEV). The vaccine is based on the Neudörfl strain of TBEV and is produced using chick embryo fibroblast cells. The virus is inactivated with formaldehyde and adsorbed onto aluminum hydroxide as an adjuvant. FSME-IMMUN induces neutralizing antibodies that target the envelope protein E of TBEV, preventing viral entry into host cells and facilitating immune clearance. It provides protection against all major subtypes of TBEV circulating globally. Originally developed by Immuno AG (later Baxter International), it has been marketed for over 40 years and acquired by Pfizer in 2014[1][3][4][5][6].
- Brand names
- FSME-IMMUNTicoVac
- Other names
- Tick-borne encephalitis vaccine (whole virus, inactivated)tick-borne encephalitis virus vaccine, inactivated, with adjuvant
02
Targets
E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on FSME-IMMUN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FSME-IMMUN.